|
|
Synthesis and antiemetic activity of 1,2,3,9-tetrahydro-9-methyl-3-(4-substituted-piperazin-1-ylmethyl)-4H-carbazol-4-one derivatives |
Qigui XU1, Tianyu LIU1, Rui TIAN1, Qingeng LI1(), Deyin MA2 |
1. School of Pharmacy, Chongqing Medical University, Chongqing 400016, China; 2. Southwest Synthetic Pharmaceutical Corporation Limited, Chongqing 401147, China |
|
|
Abstract 5-HT3 receptor antagonists, such as Ondansetron, are used for anti-emesis after chemotherapy, radiotherapy and operations. Some Ondansetron analogs possessing piperazine ring as side chains were synthesized in our lab. Thus, one of the two carbonyl groups of starting material 1,3-cyclohexandione (1) was condensed with phenylhydrazine hydrochloride to form monophenylhydrazone (2). 1,2,3,9-Tetrahydro-4H-carbazol-4-one (3) was prepared from 2via cyclization and rearranged in the presence of ZnCl2. Through a methylation reaction, compound 3 was converted to 1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one (4). 3-Dimethylaminomethyl substituted compound (5) was synthesized from 4 by a Mannich reaction in glacial acetic acid. Nine novel 1,2,3,9-tetrahydro-9-methyl-3-(4-substituted-piperazin-1-ylmethyl)- 4H-carbazol-4-one derivatives (6a-6i) were synthesized through nucleophilic substitution reaction of 5 with piperazines. The structures of all the target compounds were determined by elemental analysis, IR, MS, 1H NMR and 13C NMR spectra. The results of preliminary pharmacological test show that part of the novel compounds have antiemetic activity comparable to that of the control Ondansetron.
|
Keywords
5-HT3 receptor antagonist
1
2
3
9-tetrahydro-4H-carbazol-4-one
Mannich reaction
antiemetic
|
Corresponding Author(s):
LI Qingeng,Email:liqingeng@cqmu.edu.cn
|
Issue Date: 05 March 2009
|
|
1 |
Milne R J, Heel R C. Ondansetron: therapeutic use as an antiemetic. Drugs , 1991, 41(4): 574-595 doi: 10.2165/00003495-199141040-00006
|
2 |
Markham A, Sorkin E M. Ondansetron: an update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs , 1993, 45(6): 931-952 doi: 10.2165/00003495-199345060-00006
|
3 |
Wilde M I, Markham A. Ondansetron: a review of its pharmacology and preliminary clinical findings in novel applications. Drugs , 1996, 52(5): 773-794
|
4 |
Kohler D R, Goldspiel B R. Ondansetron: a serotonin receptor (5-HT3) antagonist for antineoplastic chemotherapy-induced nausea and vomiting. DICP , 1991, 25(4): 367-380
|
5 |
Roberson C R, McLeskey C H. Ondansetron: in a class (5-HT3) of its own. Semin Anesth , 1996, 15 (1): 41-46 doi: 10.1016/S0277-0326(96)80005-5
|
6 |
Culy C R, Bhana N, Plosker G L. Ondansetron: A review of its use as an antiemetic in children. Paediatr Drugs , 2001, 3(6): 441-479 doi: 10.2165/00128072-200103060-00007
|
7 |
Hilbert M F, Hoffmann R, Miller R C, Carr A A. Conformation-Activity Relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site. J Med Chem , 1990, 33(6): 1594-1600 doi: 10.1021/jm00168a011
|
8 |
Clemo G R, Felton D G I. The Chemistry of the Carbazoles:1,2,3,4-Tetrahydro-4-ketocarbazoles. J Chem Soc , 1951, 700-702 doi: 10.1039/jr9510000700
|
9 |
Oikawa Y, Yonemitsu O. Selective oxidation of the side chain at C-3 of indoles. J Org Chem , 1977, 42: 1213-1246 doi: 10.1021/jo00427a024
|
10 |
Chen G H. Synthesis of antiemetic ondansetron. Chin J Pharm , 1993, 24(6): 241-242 (in Chinese)
|
11 |
Mongolsuk S, Robertson A, Towers R. 2,4,3',5'-Tetrahydroxystilbene from Artocarpus lakoocha. J Chem Soc , 1957, 2231-2233 doi: 10.1039/jr9570002231
|
12 |
Littell R, Greenblatt E N, Allen G R. Mannich bases of 2,3-dihydro-4(1H)-carbazolones as potential psychotropic agents. J Med Chem , 1972, 15(8), 875-876 doi: 10.1021/jm00278a033
|
13 |
Bermudez J, Boyle E A, Miner W D, Sanger G J. The anti-emetic potential of the 5-hydroxytryptamine 3 receptor antagonist BRL 43694. Br J Cancer , 1988, 58(5): 644-650
|
14 |
Stables R, Andrews P L R, Bailey H E, Costall B, Gunning S J, Hawthorn J, Naylor R J, Tyers M B. Antiemetic properties of the 5-HT3 receptor antagonist, GR 38032F. Cancer Treat Rev , 1987, 14: 333-336 doi: 10.1016/0305-7372(87)90026-0
|
15 |
Littell R, Allen G R. 3-(Morpholinomethyl)-2,3-dihydrocarbazol-4(1H)-ones. US 3634420, 1972 [Chem Abstr, 1972, 76, 72400]
|
16 |
Kuang Y Q, Zhang S Y, Sun X L. Synthesis of 1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one. Chin J Pharm , 1994, 25(1): 36-37 (in Chinese)
|
17 |
Maikeru B T. Medicine. J P 63165314, 1988 [Chem Abstr, 1989, 110, 205704]
|
18 |
Coates I H, Bell J A, Humber D C, Ewan G B. 3-Imidazolylmethyl-1,2,3,9-tetrahydro-4H-carbazol-4-one derivatives. DE 3502508, 1985 [Chem Abstr, 1986, 104, 19589]
|
19 |
Zinnes H. Process for the preparation of 4-keto-1,2,3,4-tetrahydrocarbazole. US 3892766, 1975 [Chem Abstr, 1975, 83, 178814]
|
20 |
Lu J R, Shi X Z. Synthesis of Ondansetron Hydrochloride. J China Pharm Univ , 1999, 30(4): 246-248 (in Chinese)
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|